Drug Profile
VK 5211
Alternative Names: LGD 4033; VK-5211Latest Information Update: 24 Mar 2023
Price :
$50
*
At a glance
- Originator Ligand Pharmaceuticals
- Developer Viking Therapeutics
- Class Osteoporosis therapies; Small molecules
- Mechanism of Action Selective androgen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Hip fracture; Muscular atrophy
- Discontinued Cachexia; Hypogonadism; Osteoporosis
Most Recent Events
- 31 Dec 2022 Viking Therapeutics has patents pending for VK 5211 in Australia, Europe, Chile, Argentina, Brazil, Canada, China, India, Japan, Korea, Mexico, New Zealand, South Africa, Taiwan, Venezuela, USA
- 31 Dec 2022 Viking Therapeutics receives patent allowance for VK 5211 in Australia, Europe, Chile, Argentina, Brazil, Canada, China, India, Japan, Korea, Mexico, New Zealand, South Africa, Taiwan, Venezuela, USA
- 24 Aug 2021 Phase-II clinical trials in Muscular atrophy in USA (PO), prior to August 2021 (Viking Therapeutics pipeline, August 2021)